Drug Comparison
Tirzepatide vs Liraglutide: Complete Comparison
Tirzepatide and Liraglutide are both prescribed for metabolic health, but they work differently and deliver different outcomes in clinical trials. This comparison draws on head-to-head trial data where available and parallel trial comparisons where not.
⚠️ Medical Disclaimer
This page is for educational purposes only and does not constitute medical advice. GLP-1 medications are prescription drugs. Discuss all treatment decisions with a licensed healthcare provider who knows your complete medical history. Individual results vary significantly from clinical trial averages.
Weight Loss
Tirzepatide
22.5% vs 8.0%
Lower Cash Cost
Tirzepatide
$1,086/mo vs $1,349/mo
Dosing
Tirzepatide
Weekly vs Daily
FDA Status
Approved 2023
Approved 2014
Side-by-Side Comparison Table
| Feature | Tirzepatide | Liraglutide |
|---|---|---|
| Brand Name(s) | Mounjaro, Zepbound | Victoza, Saxenda |
| Mechanism | GIP/GLP-1 dual receptor agonist | GLP-1 receptor agonist |
| FDA Status | Approved 2023 | Approved 2014 |
| Mean Weight Loss | 22.5% (SURMOUNT-1) | 8.0% (SCALE) |
| Starting Dose | 2.5 mg | 0.6 mg |
| Max Dose | 15 mg | 3.0 mg |
| Frequency | Weekly | Daily |
| Half-Life | 120 hrs | 13 hrs |
| Cash Price/Month | $1086 | $1349 |
| Prior Auth Required | Yes | Yes |
| Key Pivotal Trial | SURMOUNT-1 | SCALE |
Weight Loss Efficacy: Tirzepatide vs Liraglutide
In their respective pivotal trials, Tirzepatide achieved a mean weight loss of 22.5% (SURMOUNT-1) while Liraglutide achieved 8.0% (SCALE). This 14.5 percentage point difference represents a clinically meaningful gap, though direct head-to-head trial data between these specific agents may be limited.
Important caveat: These trials enrolled different populations (different BMI criteria, T2D vs non-diabetic, different geographies) and used different primary endpoints. Direct comparisons should be interpreted with caution.
Mechanism: How They Work Differently
Tirzepatide is a GIP/GLP-1 dual receptor agonist. Liraglutide is a GLP-1 receptor agonist. Both medications work through the GLP-1 pathway but differ in their additional receptor targets, half-lives, and molecular structures.
Side Effects
Both Tirzepatide and Liraglutide share a similar GI side effect profile. Common side effects for both include: constipation, diarrhea, fatigue, injection-site reaction. These are typically most pronounced during dose escalation and improve with time.
Tirzepatide-specific: abdominal pain. Liraglutide-specific: headache
Cost Comparison
Cash pay prices vary significantly: Tirzepatide lists at approximately $1086/month vs Liraglutide at $1349/month. Both require prior authorization through most commercial insurers.
Which Is Right for You? Decision Guide
Consider Tirzepatide if:
- ✓ Your insurance specifically covers Mounjaro
- ✓ Your prescriber has experience with Tirzepatide
- ✓ Once-weekly injection fits your schedule
- ✓ You have prior experience with GIP agonists
Consider Liraglutide if:
- ✓ Your insurance specifically covers Victoza
- ✓ Established long-term safety data is important
- ✓ You prefer daily injections for dose flexibility
- ✓ Simpler GLP-1 only mechanism is preferred
Bottom line: The choice between Tirzepatide and Liraglutide is best made with your prescribing clinician, accounting for your specific medical history, insurance coverage, prior treatment response, and metabolic goals. Neither medication is universally superior for all patients.